Ionis Pharmaceuticals (MEX:IONS) Accounts Payable : MXN357 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Ionis Pharmaceuticals Accounts Payable?

Ionis Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2025 was MXN357 Mil.

Ionis Pharmaceuticals's quarterly Accounts Payable increased from Sep. 2024 (MXN178 Mil) to Dec. 2024 (MXN896 Mil) but then declined from Dec. 2024 (MXN896 Mil) to Mar. 2025 (MXN357 Mil).

Ionis Pharmaceuticals's annual Accounts Payable increased from Dec. 2022 (MXN349 Mil) to Dec. 2023 (MXN442 Mil) and increased from Dec. 2023 (MXN442 Mil) to Dec. 2024 (MXN896 Mil).

Ionis Pharmaceuticals Accounts Payable Historical Data

The historical data trend for Ionis Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Accounts Payable Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable

Get a 7-Day Free Trial

342.12

244.20

349.39

441.79

896.04

Ionis Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable	Get a 7-Day Free Trial															217.11	169.33	178.24	896.04	357.12

Ionis Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Ionis Pharmaceuticals Accounts Payable Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (MEX:IONS) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

IONS:USA 0JDI:UK ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionis.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.